Garza at BioMedReports.com lost credibility in my view on this MCLN pick. Back in late November, he said it could reach .40 short term. Here we are months later, and it's trading at .02.
I personally would never go with another of Garza's picks after that one.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.